IL296878A - Combined administration of miradmatinib and lipirafenib for use in the treatment of cancers - Google Patents
Combined administration of miradmatinib and lipirafenib for use in the treatment of cancersInfo
- Publication number
- IL296878A IL296878A IL296878A IL29687822A IL296878A IL 296878 A IL296878 A IL 296878A IL 296878 A IL296878 A IL 296878A IL 29687822 A IL29687822 A IL 29687822A IL 296878 A IL296878 A IL 296878A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- administered
- per day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296878A true IL296878A (en) | 2022-12-01 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296878A IL296878A (en) | 2020-04-03 | 2021-04-02 | Combined administration of miradmatinib and lipirafenib for use in the treatment of cancers |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230128315A1 (https=) |
| EP (1) | EP4125842B1 (https=) |
| JP (2) | JP7748386B2 (https=) |
| KR (1) | KR20230048476A (https=) |
| CN (1) | CN116194095B (https=) |
| AU (1) | AU2021246141A1 (https=) |
| BR (1) | BR112022019914A2 (https=) |
| CA (1) | CA3174223A1 (https=) |
| CL (1) | CL2022002682A1 (https=) |
| CO (1) | CO2022015891A2 (https=) |
| DK (1) | DK4125842T3 (https=) |
| ES (1) | ES2985012T3 (https=) |
| FI (1) | FI4125842T3 (https=) |
| HU (1) | HUE067894T2 (https=) |
| IL (1) | IL296878A (https=) |
| MX (1) | MX2022012351A (https=) |
| PE (1) | PE20231211A1 (https=) |
| PL (1) | PL4125842T3 (https=) |
| PT (1) | PT4125842T (https=) |
| TW (1) | TWI893097B (https=) |
| WO (1) | WO2021202981A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3254428A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB |
| WO2023178276A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| JP2025534589A (ja) * | 2022-10-14 | 2025-10-17 | スプリングワークス、セラピューティクス、インコーポレイテッド | がんの治療に使用するための併用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013148817A (ru) * | 2011-04-01 | 2015-05-10 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и мек и способы их применения |
| CN113307805A (zh) * | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
-
2021
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 US US17/995,002 patent/US20230128315A1/en active Pending
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025120501A (ja) | 2025-08-15 |
| CN116194095A (zh) | 2023-05-30 |
| AU2021246141A1 (en) | 2022-12-01 |
| EP4125842A1 (en) | 2023-02-08 |
| KR20230048476A (ko) | 2023-04-11 |
| ES2985012T3 (es) | 2024-11-04 |
| BR112022019914A2 (pt) | 2022-12-13 |
| TW202207910A (zh) | 2022-03-01 |
| WO2021202981A1 (en) | 2021-10-07 |
| CN116194095B (zh) | 2024-09-13 |
| HUE067894T2 (hu) | 2024-11-28 |
| CO2022015891A2 (es) | 2023-05-08 |
| JP2023521036A (ja) | 2023-05-23 |
| JP7748386B2 (ja) | 2025-10-02 |
| DK4125842T3 (da) | 2024-07-22 |
| EP4125842B1 (en) | 2024-06-05 |
| PE20231211A1 (es) | 2023-08-17 |
| TWI893097B (zh) | 2025-08-11 |
| CA3174223A1 (en) | 2021-10-07 |
| PL4125842T3 (pl) | 2024-10-14 |
| MX2022012351A (es) | 2023-03-13 |
| CL2022002682A1 (es) | 2023-06-16 |
| US20230128315A1 (en) | 2023-04-27 |
| FI4125842T3 (fi) | 2024-08-06 |
| PT4125842T (pt) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7748386B2 (ja) | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 | |
| US20060035923A1 (en) | Overactive bladder treating drug | |
| CN101622013A (zh) | 包含丁丙诺啡和纳洛酮的改善的药用组合物 | |
| JP2003535110A5 (https=) | ||
| JP2022519721A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| WO2009015561A1 (en) | The use of leonurine and compositions thereof | |
| Moyao-García et al. | A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children | |
| US20230018600A1 (en) | Controlled release formulations comprising drotaverine or salt thereof | |
| WO2020249577A1 (en) | New treatment of sma | |
| JP2022520276A (ja) | ベンズイミダゾール誘導体化合物を含む医薬組成物 | |
| CN1625402A (zh) | 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途 | |
| CN110267657B (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途 | |
| US12303503B1 (en) | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | |
| KR101978459B1 (ko) | 조루증 치료용 약학 조성물 및 조루증 치료 방법 | |
| WO1998005324A1 (en) | Method for treating bipolar disorder | |
| WO2020094591A1 (en) | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia | |
| US7842702B2 (en) | Treatment for irritable bowel syndrome | |
| Quinson et al. | Steady state evaluation of two extended release (XR) nevirapine (NVP) tablets 400 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients | |
| JP2004155661A (ja) | 突然死予防剤 | |
| EP1901726A2 (en) | Composition for treatment of psychosis | |
| WO2009120054A1 (es) | Metoclopramida de liberación prolongada de 24 horas | |
| Podolsky et al. | Randomized clinical trial of the safety and efficacy of oxymorphone extended release for degenerative disc disease in opioid-naive patients | |
| Bergasa et al. | I. THE CHALLENGE OF PRURITUS COMPLICATING LIVER DISEASE | |
| Rauck et al. | Conversion and titration from oxycodone to oxymorphone extended release in patients with chronic low back pain |